Supreme Court restores access to abortion pill mifepristone

Supreme Court mifepristone access was temporarily restored on Monday after an emergency intervention that allows the abortion pill to once again be prescribed remotely and delivered by mail.

Samuel Alito issued an administrative stay blocking a lower court ruling that had restricted nationwide access to mifepristone.

Temporary relief restores telehealth access

The decision reinstates rules that allow the drug to be prescribed through telemedicine and dispensed via mail or pharmacies, without requiring an in-person doctor visit.

Those rules were originally approved by the Food and Drug Administration in 2023.

The order is temporary and is set to expire on May 11, giving the full Supreme Court of the United States time to decide whether to extend the stay while litigation continues.

Legal battle centers on safety and regulation

The case was brought by the Louisiana, which bans abortion in most cases. State officials argue that federal regulators failed to adequately consider safety risks when removing the requirement for in-person medical visits.

However, pharmaceutical companies and public health groups dispute that claim.

Manufacturers including Danco Laboratories and GenBioPro say the drug has been extensively reviewed and is safe. They also warn that restricting access would create disruption for patients, providers and pharmacies.

Lower court ruling had imposed nationwide limits

The U.S. Court of Appeals for the Fifth Circuit had issued a ruling that blocked the distribution of mifepristone by mail and barred telehealth prescriptions while the case proceeds.

That decision took effect immediately before being halted by the Supreme Court’s intervention.

A recurring fight over abortion access

This is not the first time the issue has reached the high court.

In 2024, the Supreme Court unanimously rejected a similar challenge, ruling that the plaintiffs — including anti-abortion groups and doctors — lacked legal standing.

The latest dispute, however, focuses more directly on federal regulatory authority and drug safety standards.

What happens next

The Supreme Court is expected to decide in the coming days whether to extend the stay.

Until then, access to mifepristone through telehealth and mail remains in place nationwide.

The temporary ruling restores access but leaves the broader legal fight unresolved. The final decision could have significant implications for abortion access and federal health policy across the United States.